Physician profile
Mandeep Dhami
NPI 1639154628
$12,278.12
in general payments reported to CMS, 2019-2025
65 companies · $2,875 in 2025
The $2,875 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $868 · 2021: $1,387 · 2022: $1,821 · 2023: $1,303 · 2024: $2,759 · 2025: $2,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,736 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,736.17 |
| Education | $201.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $977.58 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $860.02 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Pfizer INC. | $669.45 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $593.29 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Novartis Pharmaceuticals Corporation | $559.22 | 2019-2025 | |
| Celgene Corporation | $543.56 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genentech USA, INC. | $532.90 | 2019-2025 | Tecentriq, Phesgo, Venclexta |
| E.R. Squibb & Sons, L.L.C. | $485.78 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $478.96 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Seagen INC. | $412.43 | 2019-2025 | Adcetris, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $372.18 | 2020-2025 | |
| Incyte Corporation | $369.48 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $354.15 | 2019-2025 | |
| Gilead Sciences, INC. | $351.98 | 2022-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $313.26 | 2023-2024 | Krazati |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.92 | 2020-2025 | |
| Array Biopharma INC | $254.84 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $215.90 | 2021-2025 | Iclusig, Hyqvia, Ninlaro |
| Eisai INC. | $210.32 | 2019-2025 | |
| Lilly USA, LLC | $191.81 | 2020-2024 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $187.65 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Amgen INC. | $178.95 | 2019-2022 | |
| Epizyme, INC. | $170.53 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $153.74 | 2020-2024 | Xarelto |
| Ipsen Biopharmaceuticals, INC | $150.55 | 2020-2024 | Onivyde |
| Adc Therapeutics America, INC. | $134.22 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $129.88 | 2021-2023 | Imbruvica |
| Geron Corporation | $125.85 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $109.16 | 2024-2025 | Orserdu, Elzonris |
| Beone Medicines USA, INC. | $107.02 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $98.42 | 2019-2024 | Enhertu |
| Acrotech Biopharma INC. | $95.23 | 2021-2025 | Beleodaq |
| Pharmaessentia USA Corporation | $90.13 | 2022-2025 | Besremi |
| Exelixis INC. | $89.70 | 2019-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $87.75 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $86.99 | 2023-2025 | Zejula, Ojjaara, Jemperli |
| Karyopharm Therapeutics INC. | $84.88 | 2021-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $72.40 | 2021-2024 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.86 | 2020-2023 | Gilotrif |
| Sobi, INC | $71.70 | 2024-2025 | |
| Blueprint Medicines Corporation | $71.50 | 2022-2024 | Ayvakit |
| Dova Pharmaceuticals | $60.91 | 2019-2021 | |
| Coherus Oncology, INC. | $57.96 | 2020-2025 | Loqtorzi |
| Emd Serono, INC. | $57.86 | 2019-2025 | |
| Taiho Oncology, INC. | $51.24 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $50.24 | 2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $49.49 | 2021-2022 | |
| Beigene USA, INC. | $49.05 | 2021-2024 | Brukinsa |
| Iovance Biotherapeutics, INC. | $44.55 | 2025 | Amtagvi |
| Servier Pharmaceuticals LLC | $43.84 | 2025 | |
| Kite Pharma, INC. | $42.77 | 2020-2025 | Yescarta |
| Amag Pharmaceuticals, INC. | $41.88 | 2021-2022 | |
| Tg Therapeutics, INC. | $33.70 | 2022 | |
| Sun Pharmaceutical Industries INC. | $31.90 | 2023-2025 | Yonsa, Odomzo |
| Morphosys, US INC. | $28.90 | 2022-2023 | Monjuvi |
| Tactile Systems Technology INC | $28.80 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.31 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $25.00 | 2023 | |
| Agios Pharmaceuticals, INC. | $22.11 | 2025 | Pyrukynd |
| Myovant Sciences INC. | $20.99 | 2021 | |
| Organon LLC | $20.68 | 2023 | Ontruzant |
| Cti Biopharma Corp. | $19.84 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $18.74 | 2025 | Enjaymo |
| Aveo Pharmaceuticals, INC. | $15.31 | 2022 | |
| Puma Biotechnology, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Dhami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.